Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGE-117 in Older Patients with Postoperative Anemia
NCT05152641Phase 2Withdrawn
- Sponsor
- BioAge Labs
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TS-143 in postoperative anemia, sponsored by BioAge Labs. Primary endpoint: Time to 2.0 g/dL Increase in Hemoglobin Level. Planned start Apr 2022; status: withdrawn.
02
Drugs
TS-143
03
Conditions
postoperative anemia
Beyond the preview
Go deeper on NCT05152641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152641.